65 and older, any sex, with Polypharmacy or Dementia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Preliminary Efficacy of the Intervention to be Assessed From Primary Care Clinician's Intervention Visit Clinical Notes and EHRPrimary· 1 year
The investigators will assess the impact of the intervention by assessing the primary care clinician's documentation from the clinic visit immediately after the patient and care partner receive the intervention brochure.
The following will be evaluated:
1. Primary care clinician's documentation of discussions about medication appropriateness, safety, or effectiveness.
2. Primary care clinician's documentation of planned medication changes (new medications to be added, dose increases, dose reductions, or medications to be stopped).
3. The proportion of patients who deprescribe one or more med
Documentation of a discussion about medication appropriateness, safety, or effectiveness
Group
Value
95% CI
Intervention (Deprescribing Education)
15
Documentation of any medications being discontinued
Group
Value
95% CI
Intervention (Deprescribing Education)
7
Documentation of a new medicine being started
Group
Value
95% CI
Intervention (Deprescribing Education)
7
Documentation of actions taken as part of the deprescribing process (e.g., order a blood test)
Group
Value
95% CI
Intervention (Deprescribing Education)
7
Proportion of patients who deprescribed 1+ medicines
Group
Value
95% CI
Intervention (Deprescribing Education)
10
The proportion of patients who added 1+ new medicine
Group
Value
95% CI
Intervention (Deprescribing Education)
10
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 60 days.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The Shared Decision Making about Medication Use for People with Multiple Health Problems study will assess the feasibility and acceptability of a deprescribing educational intervention in primary care for patients with mild cognitive impairment or dementia and/or multiple chronic conditions (MCC), the patients' care partners, clinicians, and medical assistants.
The intervention consists of the following strategies: 1) a patient/caregiver component focused on education and activation about deprescribing, and 2) a clinician component focused on increasing clinician awareness about options and processes for deprescribing in the MCI/dementia and/or MCC population. Clinicians will each be asked to participate in a single, 15-minute educational session on deprescribing, and medical residents will receive a 45-minute lecture. Patients, caregivers, clinicians, and medical assistants will participate in a single one-on-one debriefing interview.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 27 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05156073.